Julian Harrison
Stock Analyst at BTIG
(4.98)
# 65
Out of 4,703 analysts
510
Total ratings
55%
Success rate
50.1%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintained: Buy | $20 → $32 | $15.52 | +106.19% | 11 | Sep 3, 2026 | |
| CNTB Connect Biopharma Holdings | Maintained: Buy | $10 | $1.84 | +443.48% | 8 | Aug 27, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $132 → $121 | $88.98 | +35.99% | 25 | Aug 26, 2026 | |
| TVRD Tvardi Therapeutics | Maintained: Buy | $5 | $1.91 | +161.78% | 9 | Aug 19, 2026 | |
| OTLK Outlook Therapeutics | Reiterated: Buy | $4 | $0.6665 | +500.15% | 22 | Aug 14, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $178 | $74.19 | +139.92% | 19 | Aug 13, 2026 | |
| LQDA Liquidia | Maintained: Buy | $109 → $111 | $68.66 | +61.67% | 47 | Aug 12, 2026 | |
| MAZE Maze Therapeutics | Maintained: Buy | $46 | $26.21 | +75.51% | 7 | Aug 11, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $151 | $92.51 | +63.23% | 13 | Aug 10, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $30 | $15.01 | +99.87% | 33 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $74 → $77 | $19.90 | +286.93% | 19 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.9747 | +310.38% | 14 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 | $19.23 | +201.61% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $44 | $9.27 | +374.65% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $21.33 | +96.91% | 5 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $58 | $30.21 | +91.99% | 8 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $38 → $39 | $22.09 | +76.55% | 25 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $175 | $114.79 | +52.45% | 15 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.08 | - | 16 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $6 | $4.58 | +31.00% | 16 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.25 | +300.00% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $487.61 | - | 19 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $3.78 | +349.74% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $22.92 | +166.14% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $82 | $145.72 | -43.73% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $0.8653 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $163 | $47.64 | n/a | 8 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.32 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $56.80 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $6.17 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $7.56 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $0.182 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.22 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $34.87 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 | $1.48 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.16 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $4.60 | n/a | 1 | Dec 9, 2020 |
Climb Bio
Sep 3, 2026
Maintained: Buy
Price Target: $20 → $32
Current: $15.52
Upside: +106.19%
Connect Biopharma Holdings
Aug 27, 2026
Maintained: Buy
Price Target: $10
Current: $1.84
Upside: +443.48%
Spyre Therapeutics
Aug 26, 2026
Rated: Buy
Price Target: $132 → $121
Current: $88.98
Upside: +35.99%
Tvardi Therapeutics
Aug 19, 2026
Maintained: Buy
Price Target: $5
Current: $1.91
Upside: +161.78%
Outlook Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $4
Current: $0.6665
Upside: +500.15%
Nektar Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $178
Current: $74.19
Upside: +139.92%
Liquidia
Aug 12, 2026
Maintained: Buy
Price Target: $109 → $111
Current: $68.66
Upside: +61.67%
Maze Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $46
Current: $26.21
Upside: +75.51%
Oruka Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $151
Current: $92.51
Upside: +63.23%
MoonLake Immunotherapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $30
Current: $15.01
Upside: +99.87%
Aug 10, 2026
Maintained: Buy
Price Target: $74 → $77
Current: $19.90
Upside: +286.93%
Aug 6, 2026
Reiterated: Buy
Price Target: $4
Current: $0.9747
Upside: +310.38%
Aug 6, 2026
Maintained: Buy
Price Target: $58
Current: $19.23
Upside: +201.61%
Aug 6, 2026
Maintained: Buy
Price Target: $44
Current: $9.27
Upside: +374.65%
Aug 5, 2026
Maintained: Buy
Price Target: $42
Current: $21.33
Upside: +96.91%
Aug 3, 2026
Initiated Coverage: Buy
Price Target: $58
Current: $30.21
Upside: +91.99%
Jul 29, 2026
Rated: Buy
Price Target: $38 → $39
Current: $22.09
Upside: +76.55%
Jun 30, 2026
Rated: Buy
Price Target: $150 → $175
Current: $114.79
Upside: +52.45%
Jun 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $17.08
Upside: -
Jun 2, 2026
Maintained: Buy
Price Target: $5 → $6
Current: $4.58
Upside: +31.00%
Mar 19, 2026
Maintained: Buy
Price Target: $1
Current: $0.25
Upside: +300.00%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $487.61
Upside: -
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $3.78
Upside: +349.74%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $22.92
Upside: +166.14%
Nov 3, 2025
Maintained: Buy
Price Target: $82
Current: $145.72
Upside: -43.73%
Mar 31, 2025
Maintained: Buy
Price Target: $14
Current: $0.8653
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $163
Current: $47.64
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $11.32
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $56.80
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $6.17
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $24
Current: $7.56
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $0.182
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.22
Upside: n/a
Apr 28, 2021
Maintained: Buy
Price Target: $12
Current: $34.87
Upside: n/a
Apr 27, 2021
Maintained: Buy
Price Target: $29
Current: $1.48
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.16
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $4.60
Upside: n/a